Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
- 15 September 2017
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 85, 133-145
- https://doi.org/10.1016/j.ejca.2017.08.020
Abstract
No abstract availableFunding Information
- Novartis Pharmaceuticals Corporation
- German Breast Group (GBG)
- Spanish Oncology Group (SOLTI)
- Breast International Group (BIG)
This publication has 43 references indexed in Scilit:
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Annals of Oncology, 2013
- Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB StudyJournal of Clinical Oncology, 2012
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase InhibitorMolecular Cancer Therapeutics, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerThe New England Journal of Medicine, 2011
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not LapatinibMolecular Cancer Therapeutics, 2010
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell linesAnnals of Oncology, 2010
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235Cancer Research, 2008
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 WeeksJournal of Clinical Oncology, 2005
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003